These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

397 related articles for article (PubMed ID: 10589763)

  • 21. Mullerian inhibiting substance binding and uptake.
    Catlin EA; Ezzell RM; Donahoe PK; Manganaro TF; Ebb RG; MacLaughlin DT
    Dev Dyn; 1992 Apr; 193(4):295-9. PubMed ID: 1511169
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Müllerian-inhibiting substance type II receptor expression and function in purified rat Leydig cells.
    Lee MM; Seah CC; Masiakos PT; Sottas CM; Preffer FI; Donahoe PK; Maclaughlin DT; Hardy MP
    Endocrinology; 1999 Jun; 140(6):2819-27. PubMed ID: 10342873
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Enhanced purification and production of Müllerian inhibiting substance for therapeutic applications.
    Donahoe PK; Clarke T; Teixeira J; Maheswaran S; MacLaughlin DT
    Mol Cell Endocrinol; 2003 Dec; 211(1-2):37-42. PubMed ID: 14656474
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Transforming growth factors type beta 1 and beta 2 are equipotent growth inhibitors of human breast cancer cell lines.
    Zugmaier G; Ennis BW; Deschauer B; Katz D; Knabbe C; Wilding G; Daly P; Lippman ME; Dickson RB
    J Cell Physiol; 1989 Nov; 141(2):353-61. PubMed ID: 2808542
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genetic studies of MIS signalling in sexual development.
    Jamin SP; Arango NA; Mishina Y; Behringer RR
    Novartis Found Symp; 2002; 244():157-64; discussion 164-8, 203-6, 253-7. PubMed ID: 11990789
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mullerian duct regression and antiproliferative bioactivities of mullerian inhibiting substance reside in its carboxy-terminal domain.
    MacLaughlin DT; Hudson PL; Graciano AL; Kenneally MK; Ragin RC; Manganaro TF; Donahoe PK
    Endocrinology; 1992 Jul; 131(1):291-6. PubMed ID: 1612008
    [TBL] [Abstract][Full Text] [Related]  

  • 27. AAV9 delivering a modified human Mullerian inhibiting substance as a gene therapy in patient-derived xenografts of ovarian cancer.
    Pépin D; Sosulski A; Zhang L; Wang D; Vathipadiekal V; Hendren K; Coletti CM; Yu A; Castro CM; Birrer MJ; Gao G; Donahoe PK
    Proc Natl Acad Sci U S A; 2015 Aug; 112(32):E4418-27. PubMed ID: 26216943
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Müllerian inhibiting substance inhibits branching morphogenesis and induces apoptosis in fetal rat lung.
    Catlin EA; Tonnu VC; Ebb RG; Pacheco BA; Manganaro TF; Ezzell RM; Donahoe PK; Teixeira J
    Endocrinology; 1997 Feb; 138(2):790-6. PubMed ID: 9003016
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Differential expression of anti-Müllerian hormone (amh) and anti-Müllerian hormone receptor type II (amhrII) in the teleost medaka.
    Klüver N; Pfennig F; Pala I; Storch K; Schlieder M; Froschauer A; Gutzeit HO; Schartl M
    Dev Dyn; 2007 Jan; 236(1):271-81. PubMed ID: 17075875
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Down-regulation of transforming growth factor beta receptors by androgen in ovarian cancer cells.
    Evangelou A; Jindal SK; Brown TJ; Letarte M
    Cancer Res; 2000 Feb; 60(4):929-35. PubMed ID: 10706107
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Müllerian inhibiting substance as a model for the transforming growth factor-beta family: development of new treatment strategies.
    Shah PC; Simpson BB; Donahoe PK
    Semin Pediatr Surg; 1996 Aug; 5(3):182-90. PubMed ID: 8858765
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sexually dimorphic expression of a teleost homologue of Müllerian inhibiting substance during gonadal sex differentiation in Japanese flounder, Paralichthys olivaceus.
    Yoshinaga N; Shiraishi E; Yamamoto T; Iguchi T; Abe S; Kitano T
    Biochem Biophys Res Commun; 2004 Sep; 322(2):508-13. PubMed ID: 15325259
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Müllerian inhibiting substance blocks epidermal growth factor receptor phosphorylation in fetal rat lung membranes.
    Catlin EA; Uitvlugt ND; Donahoe PK; Powell DM; Hayashi M; MacLaughlin DT
    Metabolism; 1991 Nov; 40(11):1178-84. PubMed ID: 1943746
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The serine/threonine transmembrane receptor ALK2 mediates Müllerian inhibiting substance signaling.
    Visser JA; Olaso R; Verhoef-Post M; Kramer P; Themmen AP; Ingraham HA
    Mol Endocrinol; 2001 Jun; 15(6):936-45. PubMed ID: 11376112
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antibody against avian müllerian inhibiting substance (MIS) recognizes MIS on rat müllerian duct and human tumor cells.
    Wang JJ; Teng CS
    Proc Natl Sci Counc Repub China B; 1989 Oct; 13(4):267-75. PubMed ID: 2484046
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Roles of estrogen receptor alpha (ER alpha) in the regulation of the human Müllerian inhibitory substance (MIS) promoter.
    Chen G; Shinka T; Kinoshita K; Yan HT; Iwamoto T; Nakahori Y
    J Med Invest; 2003 Aug; 50(3-4):192-8. PubMed ID: 13678390
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mullerian Inhibiting Substance inhibits cervical cancer cell growth via a pathway involving p130 and p107.
    Barbie TU; Barbie DA; MacLaughlin DT; Maheswaran S; Donahoe PK
    Proc Natl Acad Sci U S A; 2003 Dec; 100(26):15601-6. PubMed ID: 14671316
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Female mice chimeric for expression of the simian virus 40 TAg under control of the MISIIR promoter develop epithelial ovarian cancer.
    Connolly DC; Bao R; Nikitin AY; Stephens KC; Poole TW; Hua X; Harris SS; Vanderhyden BC; Hamilton TC
    Cancer Res; 2003 Mar; 63(6):1389-97. PubMed ID: 12649204
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The inhibitory effects of müllerian-inhibiting substance on epidermal growth factor induced proliferation and progesterone production of human granulosa-luteal cells.
    Kim JH; Seibel MM; MacLaughlin DT; Donahoe PK; Ransil BJ; Hametz PA; Richards CJ
    J Clin Endocrinol Metab; 1992 Sep; 75(3):911-7. PubMed ID: 1517385
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Natural mutations of the anti-Mullerian hormone type II receptor found in persistent Mullerian duct syndrome affect ligand binding, signal transduction and cellular transport.
    Belville C; Maréchal JD; Pennetier S; Carmillo P; Masgrau L; Messika-Zeitoun L; Galey J; Machado G; Treton D; Gonzalès J; Picard JY; Josso N; Cate RL; di Clemente N
    Hum Mol Genet; 2009 Aug; 18(16):3002-13. PubMed ID: 19457927
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.